Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?
Merck (MRK) and Daiichi Sankyo withdrew a U.S. application for ifinatamab deruxtecan in lung cancer due to insufficient evidence. Phase 2 showed 48.2% tumor response, but no comparison to chemotherapy. Phase 3 trial enrollment is nearly complete. FDA had previously placed the trial on hold due to safety concerns. No new filing timeline was announced, delaying potential revenue and requiring further research spending.
How this was made
The 30-second read
Why it matters
Regulatory withdrawal removes an imminent approval milestone, extending the development timeline and increasing R&D costs, which may depress share prices.
Market read
The news directly affects MRK and DSKY shares, with broader implications for oncology ADC investors.
What to watch
Potential for the drug to succeed in later‑stage trials or in other indications could mitigate short‑term impact.
Background
Merck and Daiichi Sankyo withdrew their joint FDA filing for a lung‑cancer antibody‑drug conjugate after discussions with the agency indicated the data did not meet accelerated‑approval criteria.
Ticker impact
Merck voluntarily withdrew the U.S. FDA application for ifinatamab deruxtecan, removing a pending accelerated‑approval opportunity.
likely downward pressure as investors price in delayed approval and additional R&D spend
Regulatory setback removes a scheduled approval date; no replacement timeline was given, increasing uncertainty.
Market effects
Sets a cautious tone for the oncology ADC space, highlighting safety hurdles.
U.S. biotech sector may see slight pullback amid heightened regulatory scrutiny.
Limited to companies with similar lung‑cancer pipelines; no broad macro effect.
Counterpoint
If the safety profile improves, the delayed launch could capture a larger market with less competition.
Key entities
- companyMerck & Co., Inc.
U.S. pharmaceutical giant, ticker MRK.
- companyDaiichi Sankyo Co., Ltd.
Japanese pharma partner, ticker DSKY.
